At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VERA Vera Therapeutics, Inc.
Trading 02-12 10:08:00 EST
41.78
-1.18
-2.75%
High43.49Low41.46Vol54.25K
Open43.46D1 Closing42.96Amplitude4.73%
Mkt Cap2.93BTradable Cap2.10BTotal Shares70.07M
T/O2.30MT/O Rate0.11%Tradable Shares50.20M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  02-07
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Files Initial Beneficial Ownership Statement for Chief Commercial Officer Laurence Matthew Skelton
Reuters  ·  01-31
Vera Therapeutics Files Initial Beneficial Ownership Statement for Chief Commercial Officer Laurence Matthew Skelton
Press Release: Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
Dow Jones  ·  01-28
Press Release: Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
Assessing Vera Therapeutics (VERA) Valuation After Phase Three Success And AI Drug Discovery Progress
Simply Wall St.  ·  01-27
Assessing Vera Therapeutics (VERA) Valuation After Phase Three Success And AI Drug Discovery Progress
Vera Therapeutics Grants Stock Options and RSUs to New Employees Under 2024 Inducement Plan
Reuters  ·  01-10
Vera Therapeutics Grants Stock Options and RSUs to New Employees Under 2024 Inducement Plan
BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's
Reuters  ·  01-08
BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's
BUZZ-U.S. STOCKS ON THE MOVE-Hershey, Praxis Precision, Cal-Maine Foods
Reuters  ·  01-07
BUZZ-U.S. STOCKS ON THE MOVE-Hershey, Praxis Precision, Cal-Maine Foods
BUZZ-Vera soars as FDA accepts priority review for kidney disease drug
Reuters  ·  01-07
BUZZ-Vera soars as FDA accepts priority review for kidney disease drug
Vera Therapeutics Shares up 14.4% Premarket After Co Receives U.S. FDA Priority Review for Kidney Disease Drug
THOMSON REUTERS  ·  01-07
Vera Therapeutics Shares up 14.4% Premarket After Co Receives U.S. FDA Priority Review for Kidney Disease Drug
BRIEF-Vera Therapeutics Announces U.S. FDA Granted Priority Review To Biologics License Application
Reuters  ·  01-07
BRIEF-Vera Therapeutics Announces U.S. FDA Granted Priority Review To Biologics License Application
FDA Grants Priority Review to Vera Therapeutics' Atacicept for IgA Nephropathy
Reuters  ·  01-07
FDA Grants Priority Review to Vera Therapeutics' Atacicept for IgA Nephropathy
Vera Therapeutics Inc - Atacicept Receives FDA Breakthrough Therapy Designation for Igan
THOMSON REUTERS  ·  01-07
Vera Therapeutics Inc - Atacicept Receives FDA Breakthrough Therapy Designation for Igan
Vera Therapeutics Inc: FDA Assigned Pdufa Target Action Date of July 7, 2026.
THOMSON REUTERS  ·  01-07
Vera Therapeutics Inc: FDA Assigned Pdufa Target Action Date of July 7, 2026.
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults With Iga Nephropathy
THOMSON REUTERS  ·  01-07
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults With Iga Nephropathy
Vera Therapeutics Inc: FDA Assigned Pdufa Target Action Date of July 7, 2026.
THOMSON REUTERS  ·  01-07
Vera Therapeutics Inc: FDA Assigned Pdufa Target Action Date of July 7, 2026.
Vera Therapeutics (VERA): Reassessing Valuation After Analyst Upgrades and Cash Boost for Atacicept Launch Prospects
Simply Wall St.  ·  2025-12-23
Vera Therapeutics (VERA): Reassessing Valuation After Analyst Upgrades and Cash Boost for Atacicept Launch Prospects
Vera Therapeutics Is Maintained at Buy by B of A Securities
Dow Jones  ·  2025-12-20
Vera Therapeutics Is Maintained at Buy by B of A Securities
Vera Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones  ·  2025-12-20
Vera Therapeutics Is Maintained at Overweight by JP Morgan
Vera Therapeutics Inc : Bofa Global Research Raises Price Objective to $66.00 From $48.00
THOMSON REUTERS  ·  2025-12-19
Vera Therapeutics Inc : Bofa Global Research Raises Price Objective to $66.00 From $48.00
Vera Therapeutics Chief Legal Officer Jason Carter Departs
Reuters  ·  2025-12-18
Vera Therapeutics Chief Legal Officer Jason Carter Departs

Introduction

Company Name.
Vera Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Issue price:
--